Endometrial hyperplasia is rare pathology for young women. It poses unique challenges of managing the hyperplasia in order to minimise risk of cancerous change while attempting to preserve fertility and maintain hormonal status.

Being able to quantify risk of developing a malignancy, or the chance in situ cancer is also vital when counselling patients.

In addition, definitive surgical treatment raises further questions regarding ovarian preservation and pelvic lymphadenectomy should an in situ cancer be discovered.

These issues will be discussed during this presentation.